Indexé dans
  • Ouvrir la porte J
  • Genamics JournalSeek
  • Clés académiques
  • JournalTOCs
  • RechercheBible
  • Infrastructure nationale des connaissances en Chine (CNKI)
  • Scimago
  • Répertoire des périodiques d'Ulrich
  • Bibliothèque des revues électroniques
  • RechercheRef
  • Université Hamdard
  • EBSCO AZ
  • OCLC - WorldCat
  • Catalogue en ligne SWB
  • Bibliothèque virtuelle de biologie (vifabio)
  • Publions
  • MIAR
  • Services d'indexation scientifique (SIS)
  • Pub européen
  • Google Scholar
Partager cette page
Dépliant de journal
Flyer image

Abstrait

Novel Nanosized Gd3+-ALGD-G2-C595: In vivo Dual Selective MUC-1 Positive Tumor Molecular MR Imaging and Therapeutic Agent

Mehdi Mirzaei, Mohammadali Mohagheghi, Daryoush Shahbazi-Gahrouei and Alireza Khatami

Scope of this study is to synthesize a nano-dendrimer and its conjugate with C595 MAb against breast cancer cell, followed by its chelating agent with Gd3+. At the end, its use as a dual nanosized probe for detection and treatment was investigated. Anti-MUC-1 MAb C595 was coupled to a biodegradable biocompatible anionic linear globular dendrimer, ALGDG2, Poly ethylene glycol PEG core and citric acid shell followed by loading with Gd3+ to make novel MR imaging contrast agents. Anticancer effects and MR imaging parameters of the prepared nanoconjugate was investigated in vitro: cell toxicity, apoptosis and TNF-alpha, hemolysis, LDH evaluations as well as toxicity, biodistribution and MR imaging of cancer place were investigated. Results showed good tumor accumulation and detection, no in vivo toxicity, and potential selective anti-breast cancer activity. In conclusion, findings of this study showed that Gd3+-ALGDG2-C595 nano-probe is potentially both, a selective breast molecular imaging tool as well as a therapeutic agent. Further, subsequent clinical trials appear warranted.